X: thread calls invest in food system

An X thread published on May 21 argued that the debate over obesity treatment should not center only on high-cost drugs such as retatrutide, but on broader investment in healthier and more affordable food. The post, from the account chooserich, contrasted pharmaceutical treatment with what it described as funding a better food system. The post circulated as Eli Lilly released new Phase 3 data on retatrutide, an experimental obesity medicine that is not yet approved in the United States. Lilly said the drug helped many trial participants lose large amounts of weight, while public-health agencies continue to describe obesity and food access as separate but overlapping challenges. ### What exactly did the X post argue? The May 21 post said society was weighing whether to keep “poisoning” people and then treating the consequences with drugs, or to invest in a food system that makes healthy eating more accessible. The thread referred to retatrutide as an example of a powerful but expensive pharmaceutical response to obesity, according to the social-media post cited in the briefing. The post also referred to hypothetical scenarios in which the drug could sharply reduce obesity prevalence. (investor.lilly.com) The social-media argument did not cite a new policy proposal, company filing or government action. It instead reflected a familiar split in the obesity debate: whether treatment should focus primarily on medicines for individuals, food-system changes, or both. CDC and USDA materials show that federal agencies already frame obesity, diet quality and food access as linked public-health issues. (investor.lilly.com) ### What do the new retatrutide numbers actually show? Eli Lilly said on May 21 that participants taking 12 mg of retatrutide in the TRIUMPH-1 Phase 3 obesity trial lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks. Lilly also said 45.3% of participants on that dose achieved at least 30% weight loss, and 65.3% fell below a body mass index of 30 by week 80. The trial enrolled adults with obesity or overweight and at least one weight-related condition, without diabetes, the company said. (cdc.gov) Ania Jastreboff of Yale School of Medicine, the trial’s lead investigator, said in Lilly’s release that people with severe obesity on the highest dose lost about 30% of body weight over two years. Lilly said a study extension showed participants with a baseline BMI of at least 35 who stayed on 12 mg lost an average of 85 pounds, or 30.3%, at 104 weeks. (investor.lilly.com) ### Is the “over 80%” figure about obesity rates? The “over 80%” framing appears to conflate different trial measures rather than a documented nationwide drop in obesity rates. Lilly’s May 21 release said 65.3% of people on the 12 mg dose moved below a BMI of 30 at 80 weeks, while an earlier research summary said 83% of participants in one trial achieved at least 15% weight reduction at 48 weeks. Those are trial endpoints, not a measured reduction in the overall U.S. obesity rate. (investor.lilly.com) CDC data updated in December 2025 said adult obesity prevalence remained high across the United States, with maps based on 2024 survey data. Federal health agencies do not describe retatrutide as having already reduced national obesity prevalence. ### What evidence is there for the food-system side of the argument? (investor.lilly.com) USDA says the Healthy Food Financing Initiative is a public-private program meant to expand access to healthy food in underserved communities. CDC says fruit and vegetable voucher incentives and produce prescription programs can improve affordability and access to healthier food. Those programs address the kind of food-system investment the X thread was calling for, though the post itself did not name a specific bill or funding stream. (cdc.gov) USDA’s January 2025 Thrifty Food Plan estimated a nutritious, cost-conscious diet for a reference family of four at $229.20 a week, or $992.90 a month, with meals prepared at home. USDA says that plan is used to calculate SNAP benefits, underscoring how federal nutrition policy already ties healthy eating to affordability. (rd.usda.gov) ### Where does this leave the drug itself? Retatrutide is still investigational. Lilly’s release described TRIUMPH-1 as a Phase 3 trial, and outside coverage said the company had not yet submitted the drug for FDA approval as of May 21, though an application could come before the end of 2026. More detailed trial data are scheduled for presentation next month at the American Diabetes Association Scientific Sessions, according to industry coverage. (fns-prod.azureedge.us) (investor.lilly.com)